

## Switzerland

### Recent and planned developments in pharmaceutical policies 2015

#### Pre-launch activities: horizon scanning and forecasting

D E V E L O P M E N T S	<b>Changes in pricing</b>	<b>Changes in reimbursement</b>
	<ul style="list-style-type: none"> <li>• <u>Revision of the health insurance law until 1.6. 2015:</u></li> <li>• More transparency in processes for SL-admission (positive list).</li> <li>• <u>EPR/ IPR (daily costs/ cost per cure):</u> External price referencing will be considered stronger than internal price referencing (daily costs/ cost per cure): EPR:IPR = 2:1.  Prices higher (at most 5% higher than the European average) than the European average price will be accepted.</li> <li>• <u>Changes in the country basket in EPR:</u> From 2015 onwards, Belgium, Finland and Sweden will be added to Austria, Denmark, the Netherlands, France, Germany and UK.</li> </ul>	<p>There are no changes planned in reimbursement.</p>
<b>Other changes 2015</b>		
<ul style="list-style-type: none"> <li>• The impact of a reference pricing system for biosimilars and generics will be analysed.</li> </ul>		
S P E C I A L T O P I C	<b>Pre-launch pharmaceutical policies: Horizon Scanning and Forecasts</b>	
	<p><b><u>Implementation of benefit Assessment:</u></b></p> <ul style="list-style-type: none"> <li>- Objective and logical assessment of added benefit (assessment of benefits and harms of medical interventions)</li> <li>- Evaluation of added benefit compared to the standard of care</li> <li>- More transparency</li> <li>- Benefit categories as a basis for a possibly higher price compared to the standard of care.</li> </ul>	